(Q37452849)

20 August 2017

1 reference

title

The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents (English)

1 reference

20 August 2017

5

Francis Giles

1 reference

20 August 2017

Kamalesh Sankhala

1

1 reference

20 August 2017

Alain Mita

2

1 reference

20 August 2017

Kevin Kelly

3

1 reference

20 August 2017

Devalingam Mahalingam

4

1 reference

20 August 2017

Monica Mita

6

1 reference

20 August 2017

publication date

21 April 2009

1 reference

20 August 2017

1 reference

20 August 2017

volume

4

1 reference

20 August 2017

issue

2

1 reference

20 August 2017

page(s)

135-142

1 reference

https://scigraph.springernature.com/pub.10.1007/s11523-009-0107-z

20 August 2017

exact match

0 references

cites work

The epidermal growth factor receptor pathway: a model for targeted therapy

1 reference

12 December 2020

Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study

1 reference

12 December 2020

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer

1 reference

12 December 2020

Kaposi's sarcoma and mTOR: a crossroad between viral infection neoangiogenesis and immunosuppression

1 reference

12 December 2020

Sirolimus-associated pulmonary toxicity

1 reference

12 December 2020

Amino acid and insulin signaling via the mTOR/p70 S6 kinase pathway. A negative feedback mechanism leading to insulin resistance in skeletal muscle cells

1 reference

12 December 2020

Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic.

1 reference

12 December 2020

Insulin regulates lipoprotein lipase activity in rat adipose cells via wortmannin- and rapamycin-sensitive pathways

1 reference

12 December 2020

Interstitial pneumonitis associated with sirolimus (rapamycin) therapy after liver transplantation

1 reference

12 December 2020

Hyperlipidaemia and post-heparin lipase activities in renal transplant recipients treated with sirolimus or cyclosporin A

1 reference

12 December 2020

Role of the insulin-like growth factor family in cancer development and progression

1 reference

12 December 2020

A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies

1 reference

12 December 2020

Exploiting the PI3K/AKT pathway for cancer drug discovery

1 reference

12 December 2020

Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features

1 reference

12 December 2020

mTOR inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes

1 reference

12 December 2020

Effect of sirolimus on the metabolism of apoB100- containing lipoproteins in renal transplant patients

1 reference

12 December 2020

Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients: risk factors, incidence, progression, and management

1 reference

12 December 2020

Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer

1 reference

12 December 2020

Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors

1 reference

12 December 2020

Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies

1 reference

12 December 2020

Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma

1 reference

12 December 2020

Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies

1 reference

12 December 2020

Rapamycin: clinical results and future opportunities

1 reference

12 December 2020

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

1 reference

12 December 2020

Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients

1 reference

12 December 2020

A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts

1 reference

12 December 2020

Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group

1 reference

12 December 2020

Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus

1 reference

12 December 2020

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

1 reference

12 December 2020

Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study

1 reference

12 December 2020

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

1 reference

12 December 2020

Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients

1 reference

12 December 2020

Hyperlipidemia in renal transplant recipients treated with sirolimus (rapamycin)

1 reference

12 December 2020

Sirolimus for Kaposi's sarcoma in renal-transplant recipients

1 reference

12 December 2020

A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer.

1 reference

12 December 2020

10.1007/S11523-009-0107-Z

Identifiers

DOI

1 reference

20 August 2017

1 reference